Literature DB >> 16194828

Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma.

Yasuhiro Ito1, Hiroshi Yoshida, Chisato Tomoda, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Hironao Yasuoka, Kennichi Kakudo, Hidenori Inohara, Kanji Kuma, Akira Miyauchi.   

Abstract

AIMS: Galectin-3, a member of the beta-galactoside binding family of lectins, has been regarded as a useful tool for discriminating malignant tumours from benign nodules of the thyroid, including the distinction between follicular carcinoma and adenoma. However, there are follicular tumours with unclear vascular or capsular invasion, which makes diagnosis more difficult. In this study, we investigated the relationship between galectin-3 expression and the degree of vascular or capsular invasion of follicular tumours.
METHODS: We immunohistochemically investigated galectin-3 expression in 260 cases of follicular tumour with various degrees of vascular or capsular invasion classified into four categories.
RESULTS: The galectin-3 expression level significantly increased with the degree of vascular or capsular invasion (p<0.0001). However, its diagnostic value for follicular carcinoma was not high because the sensitivity and specificity were 68.7% and 57.5%, respectively.
CONCLUSIONS: Our findings suggest that galectin-3 plays a role in the transformation of follicular tumours from benign to malignant; however, when diagnosing follicular tumours, the presence of this protein should not be required for diagnosing malignant transformation in all cases. Therefore, we must conclude that galectin-3 should only be considered an adjuvant marker for follicular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16194828     DOI: 10.1080/00313020500169545

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  8 in total

Review 1.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

2.  Imp3 expression in benign and malignant thyroid tumors and hyperplastic nodules.

Authors:  Sezer Kulaçoğlu; Gamze Erkılınç
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

3.  Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma.

Authors:  Asli Nar; Ozlem Ozen; Neslihan Bascil Tutuncu; Beyhan Demirhan
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

4.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Authors:  Magdalena Slosar; Poonam Vohra; Manju Prasad; Andrew Fischer; Robert Quinlan; Ashraf Khan
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

6.  Diagnostic and prognostic markers in differentiated thyroid cancer.

Authors:  José M Gómez Sáez
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

7.  Computerized nuclear morphometry in the diagnosis of thyroid lesions with predominant follicular pattern.

Authors:  Ha Aiad; Ag Abdou; Ma Bashandy; An Said; Ss Ezz-Elarab; Aa Zahran
Journal:  Ecancermedicalscience       Date:  2009-09-17

8.  Needle Tract Seeding of Thyroid Follicular Carcinoma after Fine-Needle Aspiration.

Authors:  Yuxin Guo; Adrian Jit Hin Koh
Journal:  Case Rep Otolaryngol       Date:  2020-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.